Register by & Save up to $400!
4th Annual Circulating Cell-Free DNA | Part of the Molecular Medicine Tri-Conference | | San Francisco
Recently, both the European Medicines Agency and the United States Food and Drug Administration approved a PCR-based cell-free DNA test to detect EGFR mutations in NSCLC as an alternative to molecular testing of tumor tissue, moving liquid biopsies closer to becoming a standard precision oncology tool.
At Cambridge Healthtech Institute's Fourth Annual Circulating Cell-Free DNA, leading researchers from academia and industry will come together to address advances as well as existing challenges in this rapidly growing field. This year's event will place emphasis on early detection, monitoring treatment response, and moving cfDNA into clinical practice.
Featured Presentations Include:
Make the Most of Your Time at Molecular Medicine Tri-ConferenceCHOOSE FROM 14 CONFERENCE TRACKS, 7 SYMPOSIA PROGRAMS, AND 27 SHORT COURSES
Dinner Short Course*
Liquid Biopsy Technologies and Applications
Flow Cytometry and Phenotypic Cell Analysis in Immuno-Oncology
Circulating Tumor Cells and Liquid Biopsy
Circulating Cell-Free DNA
Wednesday, November 23, 2016
Liquid Biopsy as a Precision Oncology Tool - Registration Deadline this Friday
Posted by Mohammed Iftekhar